MCID: LYM133
MIFTS: 71

Lymphoma, Hodgkin, Classic

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Lymphoma, Hodgkin, Classic

MalaCards integrated aliases for Lymphoma, Hodgkin, Classic:

Name: Lymphoma, Hodgkin, Classic 57 75 38 40
Hodgkin Lymphoma 57 12 76 53 37 29 13 6
Hodgkin Disease 57 12 53 75 55 43 73
Hodgkin's Lymphoma 38 12 53 15
Chl 57 75
Hodgkin's Disease of Lymph Nodes of Inguinal Region and/or Lower Limb 73
Hodgkin's Disease of Intrapelvic Lymph Nodes 73
Stage Ii Subdiaphragmatic Hodgkin Lymphoma 12
Stage I Subdiaphragmatic Hodgkin Lymphoma 12
Lymphoma, Hodgkin, Susceptibility to 40
Hodgkin Lymphoma, Susceptibility to 57
Classic Hodgkin Lymphoma 59
Classic Hodgkin Disease 59
Lymphoma, Hodgkin's 53
Hodgkin's Sarcoma 12
Hodgkins Lymphoma 12
Hodgkin's Disease 76
Hl 12

Characteristics:

Orphanet epidemiological data:

59
classic hodgkin lymphoma
Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-5/10000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: any age;

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
lymphoma, hodgkin, classic:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Lymphoma, Hodgkin, Classic

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 98293Disease definitionHodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases.EpidemiologyHL is an uncommon cancer with an incidence of about 1/40,000 in North America and Europe. There are about 8500 new cases reported in the U.S. each year.Clinical descriptionHL is comprised of 2 major forms: classical Hodgkin lymphoma (CHL; see this term), seen in 95% of all HL cases, and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL; see this term), seen in only 5% of all HL cases. Disease onset occurs most frequently in young adults (age 15-35) followed by older adults (over the age of 55) and usually begins with the painless swelling of a lymph node in the upper body. Disease can spread to multiple lymph node regions or lymphoid structures and associated systemic symptoms (weight loss > 10% of baseline, fevers, night sweats) are observed in about 20% of patients.EtiologyThe exact cause is unknown but immunological, genetic and environmental factors are thought to be involved.Management and treatmentTreatment with radiotherapy and systemic chemotherapy leads to a very good prognosis. Follow-up physical exams, blood tests and x-rays are needed to check for recurrence and check for any long-term side effects of the toxic treatments. Possible long-term side effects include secondary cancers, infertility, reduced immunity, thyroid problems, heart disease and stroke.PrognosisThe international prognostic score (IPS) is a score given based on the presence of 7 risk factors (male sex, >45 years of age, stage 4 disease, serum albumin 15,000/mm3) at the time of diagnosis. The more factors present, the less favorable the prognosis. The cure rates are 90% for early-stage HL and 70% for advance stage HL.Visit the Orphanet disease page for more resources.

MalaCards based summary : Lymphoma, Hodgkin, Classic, also known as hodgkin lymphoma, is related to lymphoma and follicular lymphoma. An important gene associated with Lymphoma, Hodgkin, Classic is KLHDC8B (Kelch Domain Containing 8B), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Viral carcinogenesis. The drugs Adcetris and Bexxar have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are hyperhidrosis and ataxia

OMIM : 57 Classic Hodgkin lymphoma is a lymph node cancer of germinal center B-cell origin. Hodgkin lymphoma tumors consist of a minority of malignant cells, known as 'Reed-Sternberg' (RS) cells, mixed with reactive lymphocytes and other benign inflammatory cells. A defining feature of RS cells is the presence of 2 nuclei (summary by Salipante et al., 2009). (236000)

UniProtKB/Swiss-Prot : 75 Lymphoma, Hodgkin, classic: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed- Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.

MedlinePlus : 43 Hodgkin disease is a type of lymphoma. Lymphoma is a cancer of a part of the immune system called the lymph system. The first sign of Hodgkin disease is often an enlarged lymph node. The disease can spread to nearby lymph nodes. Later it may spread to the lungs, liver, or bone marrow. The exact cause is unknown. Hodgkin disease is rare. Symptoms include Painless swelling of the lymph nodes in the neck, armpits, or groin Fever and chills Night sweats Weight loss Loss of appetite Itchy skin To diagnose Hodgkin disease, doctors use a physical exam and history, blood tests, and a biopsy. Treatment depends on how far the disease has spread. It often includes radiation therapy or chemotherapy. The earlier the disease is diagnosed, the more effective the treatment. In most cases, Hodgkin disease can be cured. NIH: National Cancer Institute

Disease Ontology : 12 A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell.

Wikipedia : 76 Hodgkin\'s lymphoma (HL) is a type of lymphoma which is generally believed to result from white blood... more...

Related Diseases for Lymphoma, Hodgkin, Classic

Diseases related to Lymphoma, Hodgkin, Classic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 102)
# Related Disease Score Top Affiliating Genes
1 lymphoma 31.8 ALK BCL6 KLHDC8B PAX5 PVT1
2 follicular lymphoma 29.8 BCL6 IRF4 MIR155
3 anaplastic large cell lymphoma 29.7 ALK PAX5 PTPRC TNFSF8
4 leukemia, chronic lymphocytic 28.9 BCL6 MIR140 MIR155 MIR21 PAX5 TNFSF8
5 lymphoma, non-hodgkin, familial 28.6 ALK BCL6 IRF4 PAX5 PTPRC TNFSF8
6 b-cell lymphomas 28.5 BCL6 IRF4 MIR20A PAX5 PVT1 TIA1
7 classic hodgkin lymphoma, mixed cellularity type 12.3
8 classic hodgkin lymphoma, lymphocyte-rich type 12.3
9 hepatic lipase deficiency 12.0
10 hydrolethalus syndrome 1 11.5
11 hodgkin's lymphoma, lymphocytic-histiocytic predominance 11.4
12 lymphoma, hodgkin, x-linked pseudoautosomal 11.2
13 cholestasis-lymphedema syndrome 11.1
14 3-hydroxy-3-methylglutaryl-coa lyase deficiency 11.0
15 lipase deficiency, combined 11.0
16 gray zone lymphoma 10.9
17 hypertrichosis lanuginosa congenita 10.9
18 lymphoproliferative syndrome 1 10.9
19 polymyositis 10.9 MIR155 MIR21
20 sarcoidosis 1 10.9
21 lymphoma, hodgkin, y-linked pseudoautosomal 10.9
22 hodgkin's paragranuloma 10.9
23 hodgkin's granuloma 10.9
24 ovarian serous carcinoma 10.8 MIR200A MIR21
25 kidney cancer 10.7 MIR20A MIR21 PVT1
26 breast lymphoma 10.7 ALK BCL6
27 heart lymphoma 10.6 BCL6 PTPRC
28 leukemia, acute lymphoblastic 10.6 MIR155 MIR21 PAX5
29 oral squamous cell carcinoma 10.6 MIR140 MIR155 MIR21
30 testicular lymphoma 10.6 BCL6 PTPRC
31 thyroid cancer, nonmedullary, 1 10.5 MIR155 MIR200A MIR21 PVT1
32 intraocular lymphoma 10.5 BCL6 PAX5
33 pancreatic ductal adenocarcinoma 10.5 MIR155 MIR18A MIR21 PVT1
34 primary mediastinal large b-cell lymphoma 10.5 BCL6 IRF4
35 mature b-cell neoplasm 10.5 BCL6 PTPRC PVT1
36 lymphosarcoma 10.5 BCL6 MIR20A PTPRC
37 primary central nervous system lymphoma 10.4 BCL6 PAX5
38 lung lymphoma 10.4 ALK BCL6 PAX5
39 hodgkin's lymphoma, lymphocytic depletion 10.4 ALK PAX5 PTPRC
40 lymphomatoid papulosis 10.4 ALK TIA1
41 nodular lymphocyte predominant hodgkin lymphoma 10.4 BCL6 PAX5 PTPRC
42 glioma 10.4 MIR140 MIR20A MIR21 PVT1
43 composite lymphoma 10.4 BCL6 PAX5 TIA1
44 plasmacytoma 10.4 IRF4 PTPRC PVT1
45 burkitt lymphoma 10.3 BCL6 MIR155 PAX5 PVT1
46 peripheral t-cell lymphoma 10.3 ALK BCL6 TIA1
47 primary effusion lymphoma 10.2 BCL6 IRF4
48 melanoma 10.2 MIR140 MIR200A MIR30B MIR374A PVT1
49 epidural neoplasm 10.2 BCL6 PTPRC
50 leukemia, acute myeloid 10.1 MIR155 MIR21 MIR374A PTPRC

Graphical network of the top 20 diseases related to Lymphoma, Hodgkin, Classic:



Diseases related to Lymphoma, Hodgkin, Classic

Symptoms & Phenotypes for Lymphoma, Hodgkin, Classic

Symptoms via clinical synopsis from OMIM:

57
Lab:
polyclonal elevation of igm
impaired lymphocyte transformation with phytohemagglutinin

Heme:
hodgkin disease


Clinical features from OMIM:

236000

Human phenotypes related to Lymphoma, Hodgkin, Classic:

59 32 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 59 32 frequent (33%) Frequent (79-30%) HP:0000975
2 ataxia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001251
3 respiratory insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0002093
4 splenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001744
5 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
6 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
7 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
8 bone marrow hypocellularity 59 32 occasional (7.5%) Occasional (29-5%) HP:0005528
9 pruritus 59 32 frequent (33%) Frequent (79-30%) HP:0000989
10 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
11 peripheral neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0009830
12 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
13 migraine 59 32 occasional (7.5%) Occasional (29-5%) HP:0002076
14 hemoptysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002105
15 cellular immunodeficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0005374
16 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
17 skin rash 59 32 occasional (7.5%) Occasional (29-5%) HP:0000988
18 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
19 bone pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002653
20 lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0002665
21 osteolysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002797
22 lymphadenopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0002716
23 poor appetite 59 32 frequent (33%) Frequent (79-30%) HP:0004396
24 dyspnea 32 occasional (7.5%) HP:0002094
25 immunodeficiency 32 hallmark (90%) HP:0002721
26 neoplasm 59 Occasional (29-5%)
27 headache 32 occasional (7.5%) HP:0002315
28 polyclonal elevation of igm 32 HP:0003459
29 hodgkin lymphoma 32 HP:0012189
30 impaired lymphocyte transformation with phytohemagglutinin 32 HP:0003347

Drugs & Therapeutics for Lymphoma, Hodgkin, Classic

FDA approved drugs:

(show all 10)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
3
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
4
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
5
Mozobil 18 49 PLERIXAFOR Genzyme December 2008
6
Rituxan 18 49 RITUXIMAB Biogen IDEC, Genentech November 1997
7
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
8
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
9
Zevalin 18 49 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
10
Zydelig 18 49 IDELALISIB Gilead July 2014

Drugs for Lymphoma, Hodgkin, Classic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 563)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
3
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
4
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
8
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 13342 241903
9
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11056-06-7 5360373
10
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
11
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
12
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
13
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
14
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
15
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Antilymphocyte Serum Phase 4,Phase 2,Phase 1,Not Applicable
21 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
48
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
49
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
50
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 1247)
# Name Status NCT ID Phase Drugs
1 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
2 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
4 Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
5 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
6 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
7 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
8 Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
9 Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
10 Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma Unknown status NCT00025636 Phase 3 carmustine;cisplatin;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan;methotrexate;vincristine sulfate
11 Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma Unknown status NCT00041210 Phase 3 ABVD regimen;Stanford V regimen;dacarbazine;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
12 Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
13 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
14 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
15 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
16 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
17 P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies Unknown status NCT01854567 Phase 3
18 Exercise During Chemotherapy for Patients With Hematological Malignancies Unknown status NCT00884364 Phase 3
19 Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma Completed NCT01251107 Phase 3 Bleomycin;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Procarbazine;Prednisone;Doxorubicin;Bleomycin;Vinblastine;Dacarbazine
20 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
21 A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) Completed NCT01034163 Phase 3 Panobinostat;Placebo
22 Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma Completed NCT00433433 Phase 3 ABVD q4 weeks;BEACOPP escalated q3 weeks
23 Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
24 Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL Completed NCT01358747 Phase 3 BEACOPPesc;BEACOPPesc - ABVD - PET2
25 High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients Completed NCT00784537 Phase 2, Phase 3 ABVD;ABVD and Radiotherapy
26 Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00070187 Phase 2, Phase 3 carmustine;cyclosporine;cytarabine;etoposide;melphalan
27 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Completed NCT00003389 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine;Vincristine;Mechlorethamine;Etoposide;Prednisone;Cyclophosphamide
28 HD12 for Advanced Stages Completed NCT00265031 Phase 3 Cyclophosphamide;Adriamycin;Etoposide;Procarbazine;Prednisone;Vincristine;Bleomycin
29 HD10 for Early Stages Completed NCT00265018 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC
30 HD11 for Intermediate Stages Completed NCT00264953 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC;Etoposide;Procarbazine;Prednisone;Vincristine
31 Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease Completed NCT00002561 Phase 3 dacarbazine;doxorubicin hydrochloride;vinblastine
32 Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed NCT00928018 Phase 3 Sirolimus;Methotrexate;Tacrolimus;Cyclosporine;MMF
33 Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Completed NCT00038558 Phase 3 Filgrastim SD/01;Adriamycin;Bleomycin;Vinblastine;DTIC
34 SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease Completed NCT00002495 Phase 3 doxorubicin hydrochloride;vinblastine
35 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
36 Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease Completed NCT00003421 Phase 3 ABVD regimen;chlorambucil;dacarbazine;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
37 Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease Completed NCT00002827 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;vincristine sulfate
38 Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease Completed NCT00005578 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
39 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
40 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
41 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
42 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
43 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
44 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
45 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
46 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
47 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
48 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
49 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
50 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3

Search NIH Clinical Center for Lymphoma, Hodgkin, Classic

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Hodgkin, Classic cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoma, Hodgkin, Classic

Genetic tests related to Lymphoma, Hodgkin, Classic:

# Genetic test Affiliating Genes
1 Hodgkin Lymphoma 29 KLHDC8B

Anatomical Context for Lymphoma, Hodgkin, Classic

MalaCards organs/tissues related to Lymphoma, Hodgkin, Classic:

41
B Cells, Bone, Bone Marrow, T Cells, Lymph Node, Testes, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Hodgkin, Classic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Lymphoma, Hodgkin, Classic

Articles related to Lymphoma, Hodgkin, Classic:

(show top 50) (show all 2253)
# Title Authors Year
1
Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )
2018
2
Multimodality imaging in endomyocardial fibrosis associated with Hodgkin lymphoma. ( 29529276 )
2018
3
Paraneoplastic pemphigus without detectable anti-plakin antibodies in a patient with non-Hodgkin lymphoma. ( 29143865 )
2018
4
Classic Hodgkin lymphoma with osseous involvement mimicking Langerhans cell histiocytosis in a child. ( 29307624 )
2018
5
Calciphylaxis in a Patient With Non-Hodgkin Lymphoma: Case Report and Literature Review. ( 29478335 )
2018
6
Chemotherapy-Colchicine Interaction in a Child with Familial Mediterranean Fever and Hodgkin Lymphoma. ( 29531656 )
2018
7
Reduced Mortality Risk in the Recent Era in Early-Stage Hodgkin Lymphoma Patients Treated With Radiation Therapy With or Without Chemotherapy. ( 29153331 )
2018
8
Coping With Knife: Postoperative Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29413265 )
2018
9
Long-term follow-up of 2 patients treated with <sup>90</sup> Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma. ( 29719928 )
2018
10
Concurrent mucosa-associated lymphoid tissue lymphoma with diffuse large B-cell lymphoma transformation and Hodgkin lymphoma of the neck. ( 29427189 )
2018
11
Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. ( 29449276 )
2018
12
Primary Cardiac B-Non-Hodgkin Lymphoma Disguised as a Pacemaker Endocarditis. ( 29977733 )
2018
13
Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India. ( 29893471 )
2018
14
Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29401099 )
2018
15
Second primary cutaneous T-cell lymphoma in patients with non-Hodgkin lymphoma: a chicken-or-the-egg issue. ( 29047113 )
2018
16
R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma. ( 29537344 )
2018
17
Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma, Int. J. Mol. Sci. 2016, 17, 2127. ( 29351228 )
2018
18
Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report. ( 29419687 )
2018
19
Testicular Estrogen-Secreting Leydig Cell Tumor in 18F-FDG PET/CT: An Incidental Detection in a Patient Treated by Chemotherapy for Hodgkin Lymphoma. ( 29166332 )
2018
20
Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. ( 28332735 )
2018
21
Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival. ( 29479868 )
2018
22
Hodgkin Lymphoma With Multiple Autoimmune Disorders: Case Report and Review of the Literature. ( 29980411 )
2018
23
Evaluation of the cytotoxic response mediated by perforin and granzyme B in patients with non-Hodgkin lymphoma. ( 28679297 )
2018
24
The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor. ( 29373571 )
2018
25
Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. ( 29351986 )
2018
26
Ruxolitinib significantly enhances <i>in vitro</i> apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. ( 29515770 )
2018
27
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. ( 29978452 )
2018
28
Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. ( 29449275 )
2018
29
Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29309302 )
2018
30
Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group<sup/>. ( 29979097 )
2018
31
CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL). ( 29950528 )
2018
32
Hodgkin lymphoma in children, adolescents and young adults - a comparative study of clinical presentation and treatment outcome. ( 28760045 )
2018
33
Hemophagocytic Lymphohistiocytosis Secondary to Unknown Underlying Hodgkin Lymphoma Presenting with a Cholestatic Pattern of Liver Injury. ( 29805352 )
2018
34
Non-alcoholic Wernicke-Korsakoff syndrome heralding non-Hodgkin lymphoma progression. ( 29582179 )
2018
35
Palisading neutrophilic and granulomatous dermatitis as a presentation of Hodgkin lymphoma: A case and review. ( 29226345 )
2018
36
Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. ( 29377256 )
2018
37
Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma? ( 29650494 )
2018
38
High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. ( 28971503 )
2018
39
Classical Hodgkin lymphoma-type and monomorphic-type post-transplant lymphoproliferative disorder following liver transplantation: a case report. ( 29980871 )
2018
40
Herpes simplex reactivation after photodynamic therapy for actinic cheilitis in a patient with Non-Hodgkin Lymphoma: a possible indication for prophylaxis. ( 29512976 )
2018
41
Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy. ( 29978754 )
2018
42
Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects. ( 28118119 )
2017
43
A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy. ( 29259834 )
2017
44
Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data. ( 28737250 )
2017
45
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. ( 28893733 )
2017
46
Proton therapy in mediastinal Hodgkin lymphoma: moving from dosimetric prediction to clinical evidence. ( 28911077 )
2017
47
The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. ( 29257907 )
2017
48
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
49
Targeting non-Hodgkin Lymphoma with Blinatumomab. ( 28532177 )
2017
50
Hodgkin Lymphoma and Castleman Disease: When One Blood Disease Can Hide Another. ( 28197347 )
2017

Variations for Lymphoma, Hodgkin, Classic

ClinVar genetic disease variations for Lymphoma, Hodgkin, Classic:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KLHDC8B NM_173546.2(KLHDC8B): c.-158C> T single nucleotide variant Pathogenic rs387906223 GRCh37 Chromosome 3, 49209095: 49209095
2 KLHDC8B NM_173546.2(KLHDC8B): c.-158C> T single nucleotide variant Pathogenic rs387906223 GRCh38 Chromosome 3, 49171662: 49171662

Cosmic variations for Lymphoma, Hodgkin, Classic:

9
(show all 35)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44623 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 20
2 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 20
3 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 20
4 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 6:137881197-137881197 20
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 20
6 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 6:137878799-137878799 20
7 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 6:137878866-137878866 20
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 6:137877175-137877175 20
9 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 6:137875704-137875704 20
10 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 6:137871481-137871481 20
11 COSM6987354 STAG2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3688A>G p.M1230V 23:124100589-124100589 20
12 COSM6945907 PIM1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.94G>A p.E32K 6:37170784-37170784 20
13 COSM6975552 PAX5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.559A>T p.I187F 9:37002693-37002693 20
14 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 1:114713909-114713909 20
15 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 1:114713907-114713907 20
16 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 1:114716127-114716127 20
17 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 1:114716126-114716126 20
18 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 1:114716123-114716123 20
19 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 1:114716126-114716126 20
20 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 6:44264977-44264977 20
21 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 11:533874-533874 20
22 COSM6987350 ARID5B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.793T>G p.F265V 10:62050947-62050947 20
23 COSM3717661 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 20
24 COSM307267 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 20
25 COSM307268 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 20
26 COSM3717662 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 20
27 COSM6987351 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.64T>G p.F22V 10:62050947-62050947 20
28 COSM6987353 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3799A>G p.M1267V 23:124100589-124100589 20
29 COSM307269 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 20
30 COSM3077774 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.295T>C p.C99R 6:394899-394899 20
31 COSM307270 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.208T>A p.Y70N 17:7675125-7675125 20
32 COSM5761 CTNNB1 skin,neck,malignant melanoma,nodular c.131C>T p.P44L 3:41224643-41224643 4
33 COSM476 BRAF skin,neck,malignant melanoma,nodular c.1799T>A p.V600E 7:140753336-140753336 4
34 COSM584 NRAS skin,arm,malignant melanoma,nodular c.182A>G p.Q61R 1:114713908-114713908 3
35 COSM580 NRAS skin,arm,malignant melanoma,nodular c.181C>A p.Q61K 1:114713909-114713909 3

Copy number variations for Lymphoma, Hodgkin, Classic from CNVD:

7 (show top 50) (show all 204)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 15434 1 115570986 115748025 Copy number Hodgkin''s lymphoma
2 18148 1 144224941 245407169 Copy number Hodgkin''s lymphoma
3 21362 1 158258490 227249364 Copy number Hodgkin''s lymphoma
4 29781 1 235850830 237390561 Copy number Hodgkin''s lymphoma
5 29922 1 238038528 245407169 Copy number Hodgkin''s lymphoma
6 35390 1 6293700 18251002 Copy number Hodgkin''s lymphoma
7 37216 1 87388008 120033702 Copy number Hodgkin''s lymphoma
8 37460 1 9146813 16679690 Copy number Hodgkin''s lymphoma
9 38491 10 102895110 124244273 Copy number Hodgkin''s lymphoma
10 40197 10 125057756 126954997 Copy number Hodgkin''s lymphoma
11 40637 10 131215760 132635356 Copy number Hodgkin''s lymphoma
12 41620 10 214400 133778456 Copy number Hodgkin''s lymphoma
13 41883 10 25240974 36004765 Copy number Hodgkin''s lymphoma
14 43571 10 46999355 135111152 Copy number Hodgkin''s lymphoma
15 43572 10 46999355 48101366 Copy number Hodgkin''s lymphoma
16 43573 10 46999355 49467140 Copy number Hodgkin''s lymphoma
17 44594 10 60095355 78914295 Copy number Hodgkin''s lymphoma
18 44784 10 6277674 8346525 Copy number Hodgkin''s lymphoma
19 45116 10 67551761 78914295 Copy number Hodgkin''s lymphoma
20 46267 10 79687952 85721525 Copy number Hodgkin''s lymphoma
21 46788 10 86278375 101096913 Copy number Hodgkin''s lymphoma
22 49260 11 104569097 133732868 Copy number Hodgkin''s lymphoma
23 50177 11 115327798 134437143 Copy number Hodgkin''s lymphoma
24 52493 11 178227 35140556 Copy number Hodgkin''s lymphoma
25 57515 11 63560139 72573784 Copy number Hodgkin''s lymphoma
26 57783 11 64800000 75000000 Gain Hodgkin''s lymphoma
27 58506 11 68129639 134437143 Copy number Hodgkin''s lymphoma
28 60254 11 84447402 105734987 Copy number Hodgkin''s lymphoma
29 60677 11 89286313 104569095 Copy number Hodgkin''s lymphoma
30 64335 12 126737931 132373208 Copy number Hodgkin''s lymphoma
31 65226 12 152534 16164790 Copy number Hodgkin''s lymphoma
32 65227 12 152534 525774777 Copy number Hodgkin''s lymphoma
33 67817 12 4490384 44739500 Copy number Hodgkin''s lymphoma
34 67821 12 45000000 56400000 Gain Hodgkin''s lymphoma
35 68783 12 51500000 63100000 Gain Hodgkin''s lymphoma
36 68979 12 52417126 60370345 Copy number Hodgkin''s lymphoma
37 69531 12 55627899 56288135 Copy number Hodgkin''s lymphoma
38 70095 12 58245748 132373208 Copy number Hodgkin''s lymphoma
39 70715 12 64263728 66931770 Copy number Hodgkin''s lymphoma
40 71442 12 70000000 82000000 Gain Hodgkin''s lymphoma
41 72563 12 82669309 120958351 Copy number Hodgkin''s lymphoma
42 75245 13 18397782 106691271 Copy number Hodgkin''s lymphoma
43 75246 13 18397782 114117460 Copy number Hodgkin''s lymphoma
44 75871 13 25400000 38500000 Loss Hodgkin''s lymphoma
45 75878 13 25500000 32200000 Loss Hodgkin''s lymphoma
46 79388 13 71000000 83000000 Loss Hodgkin''s lymphoma
47 83222 14 19570807 42171562 Copy number Hodgkin''s lymphoma
48 83386 14 20383489 53262838 Copy number Hodgkin''s lymphoma
49 83387 14 20383489 56623380 Copy number Hodgkin''s lymphoma
50 85558 14 48879628 106278173 Copy number Hodgkin''s lymphoma

Expression for Lymphoma, Hodgkin, Classic

Search GEO for disease gene expression data for Lymphoma, Hodgkin, Classic.

Pathways for Lymphoma, Hodgkin, Classic

Pathways related to Lymphoma, Hodgkin, Classic according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202
2 Viral carcinogenesis hsa05203
3 Epstein-Barr virus infection hsa05169

Pathways related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 BCL6 IRF4 PAX5 PTPRC
2 11.64 MIR155 MIR18A MIR200A MIR20A MIR21 MIR30B
3 10.86 BCL6 PAX5 PTPRC

GO Terms for Lymphoma, Hodgkin, Classic

Cellular components related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 MIR140 MIR155 MIR186 MIR18A MIR20A MIR21

Biological processes related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of sprouting angiogenesis GO:1903672 9.46 MIR155 MIR30B
2 positive regulation of cardiac muscle hypertrophy GO:0010613 9.43 MIR155 MIR21
3 negative regulation of stress fiber assembly GO:0051497 9.4 MIR20A MIR21
4 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.37 MIR20A MIR21
5 positive regulation of activated T cell proliferation GO:0042104 9.33 MIR155 MIR21 MIR30B
6 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.32 MIR140 MIR21
7 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.26 MIR155 MIR20A
8 gene silencing by miRNA GO:0035195 9.23 MIR140 MIR155 MIR18A MIR200A MIR20A MIR21
9 negative regulation of regulatory T cell differentiation GO:0045590 9.13 MIR155 MIR21 MIR30B

Molecular functions related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR140 MIR155 MIR18A MIR200A MIR20A MIR21

Sources for Lymphoma, Hodgkin, Classic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....